{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33990684",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "01",
    "Day": "30"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "14"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41375-021-01266-6"
    ],
    "Journal": {
      "ISSN": "1476-5551",
      "JournalIssue": {
        "Volume": "35",
        "Issue": "9",
        "PubDate": {
          "Year": "2021",
          "Month": "Sep"
        }
      },
      "Title": "Leukemia",
      "ISOAbbreviation": "Leukemia"
    },
    "ArticleTitle": "JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.",
    "Pagination": {
      "StartPage": "2616",
      "EndPage": "2620",
      "MedlinePgn": "2616-2620"
    },
    "Abstract": {
      "AbstractText": [
        "We analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 using the Newcastle-Ottawa and Jadad scales for quality assessment. We used disease severity as a proxy for time when JAK-inhibitor therapy was started. We identified 6 cohort studies and 5 clinical trials involving 2367 subjects treated with ruxolitinib (N\u2009=\u20093) or baricitinib 45 (N\u2009=\u20098). Use of JAK-inhibitors decreased use of invasive mechanical ventilation (RR = 0.63; [95% Confidence Interval (CI), 0.47, 0.84]; P\u2009=\u20090.002) and had borderline impact on rates of intensive care unit (ICU) admission (RR = 0.24 [0.06, 1.02]; P\u2009=\u20090.05) and acute respiratory distress syndrome (ARDS; RR = 0.50 [0.19, 1.33]; P\u2009=\u20090.16). JAK-inhibitors did not decrease length of hospitalization (mean difference (MD) -0.18 [-4.54, 4.18]; P\u2009=\u20090.94). Relative risks of death for both drugs were 0.42 [0.30, 0.59] (P\u2009<\u20090.001), for ruxolitinib, RR = 0.33 (0.13, 0.88; P\u2009=\u20090.03) and for baricitinib RR = 0.44 (0.31, 0.63; P\u2009<\u20090.001). Timing of JAK-inhibitor treatment during the course of COVID-19 treatment may be important in determining impact on outcome. However, these data are not consistently reported."
      ],
      "CopyrightInformation": "\u00a9 2021. The Author(s), under exclusive licence to Springer Nature Limited."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-2079-881X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China."
          },
          {
            "Identifier": [],
            "Affiliation": "State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of ICU, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China."
          }
        ],
        "LastName": "Chen",
        "ForeName": "Chong-Xiang",
        "Initials": "CX"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Tuberculosis, Fuzhou Pulmonary Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian Province, China."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Jiao-Jiao",
        "Initials": "JJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of ICU, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Huan",
        "Initials": "H"
      },
      {
        "Identifier": [
          "0000-0002-1268-8135"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Public Health, Sun Yat-sen University, Guangzhou, China."
          }
        ],
        "LastName": "Yuan",
        "ForeName": "Le-Tao",
        "Initials": "LT"
      },
      {
        "Identifier": [
          "0000-0002-9156-1676"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology and Inflammation, Haematology Research Centre, Imperial College London, London, UK."
          }
        ],
        "LastName": "Gale",
        "ForeName": "Robert Peter",
        "Initials": "RP"
      },
      {
        "Identifier": [
          "0000-0002-4226-9580"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. liangyang@sysucc.org.cn."
          }
        ],
        "LastName": "Liang",
        "ForeName": "Yang",
        "Initials": "Y"
      }
    ],
    "GrantList": [
      {
        "GrantID": "2017ZT07S096",
        "Agency": "Guangdong Innovative and Entrepreneurial Research Team Program",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Meta-Analysis",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Leukemia",
    "NlmUniqueID": "8704895",
    "ISSNLinking": "0887-6924"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Azetidines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Janus Kinase Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Nitriles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Purines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrimidines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sulfonamides"
    },
    {
      "RegistryNumber": "82S8X8XX8H",
      "NameOfSubstance": "ruxolitinib"
    },
    {
      "RegistryNumber": "ISP4442I3Y",
      "NameOfSubstance": "baricitinib"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Azetidines"
    },
    {
      "QualifierName": [
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Janus Kinase Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Nitriles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Patient Safety"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Purines"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Pyrazoles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pyrimidines"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Sulfonamides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "RPG is a consultant to BeiGene Ltd, Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., and CStone Pharmaceuticals. Advisor: Antegene Biotech LLC, Medical Director: FFF Enterprises Inc. Partner: AZACA Inc. Board of Directors: RakFond Foundation for Cancer Research Support. Scientific Advisory Board, StemRad Ltd. All other authors declare no competing interests."
}